The United Kingdom and the United States have secured a important trade agreement that will ensure no levies on UK pharmaceutical shipments being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to raise spending on pharmaceuticals through the National Health Service (NHS). This pledge ensures that import taxes on these key products will be held at zero for a timeframe of 36 months.
This deal is in response to recent warnings to hike import taxes on patented drug products, with potential rates discussed reaching 100%.
"This arrangement between the UK bolsters the international landscape for innovative medicines and brings long-overdue fairness to American-British pharmaceutical trade," an announcement said.
Economic Importance
Drugs represent one of the the United Kingdom's most significant goods shipped to the America, which is clearly the primary market for large British pharmaceutical firms.
Trade data indicate that in the one-year period leading up to September, the UK sold drugs totaling billions to the US. This figure made up nearly one-fifth of all goods exports in that period.
"This deal secures jobs, boosts capital expenditure and facilitates the UK to emerge as a international leader for life sciences," the Business and Trade Secretary stated.
Specific British Pledges
The pact entails several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to double total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds were more than twenty percent.
Recent Tensions
The deal follows a protracted row between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
These tensions were exacerbated by claims that US consumers were paying a premium for the same drugs than patients in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been delayed or scrapped, while major expansions have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS had to spend more on drugs, noting that its budget allocation on drugs had decreased as a percentage of its resources over the past decade.
